Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia

Leuk Lymphoma. 2021 May;62(5):1178-1186. doi: 10.1080/10428194.2020.1863400. Epub 2020 Dec 29.

Abstract

Although acute myeloid leukemia (AML) with NPM1mut/FLT3-ITDneg is a low-risk entity, its relapse rate remains high. Out of 333 AML patients, 27 were NPM1mut, and were analyzed in greater detail in order to find associations between clinical and molecular features and cumulative incidence of relapse. Next-generation sequencing (NGS) was performed on diagnosis and remission samples using two capture-based panels. The presence of the FLT3D835 variant at diagnosis and a qPCR value of NPM1mut ≥0.1% after induction chemotherapy were associated with an increased probability of relapse, especially if both conditions are present together. By contrast, patients in which the main clone found at diagnosis harbored NPM1 variant had a lower risk of relapse. Nineteen of the 85 variants found at diagnosis were detected by NGS in remission. AML Subgroup with NPM1mut/FLT3-ITDneg is a heterogeneous entity, which can be further risk-stratified based on molecular biomarkers.

Keywords: Acute myeloid leukemia; FLT3; NPM1; genetic biomarkers; prognostic impact.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Mutation
  • Nuclear Proteins* / genetics
  • Nucleophosmin
  • Prognosis
  • Recurrence
  • Risk
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • NPM1 protein, human
  • Nuclear Proteins
  • Nucleophosmin
  • fms-Like Tyrosine Kinase 3